MedTrace Logo

Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty

NCT02933671 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-07-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn if using a suprainguinal fascia iliaca (SIFI) injection technique (also called a "nerve block") that numbs the nerves going to the side and front of the upper leg will improve pain control after surgery. The SIFI technique uses a numbing solution (local anesthetics) that is injected next to nerves in the hip to reduce pain. This block may affect movement in the leg and make the legs weak. The amount of leg weakness is not known and assessment of this will be included in the study. Many institutions use the SIFI block for patients having total hip replacements, with the hope of providing good pain relief combined with improved mobility after surgery.

Conditions

  • Hip Osteoarthritis
  • Primary Total Hip Arthroplasty
  • Pain

Interventions

PROCEDURE

Suprainguinal fascia iliaca (SIFI) block

An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.

PROCEDURE

Sham block

An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.

DRUG

Ropivacaine

Local anesthetic (numbing drug)

DRUG

Saline

Salt water placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-03-16
Completion
2020-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933671 on ClinicalTrials.gov